Reuters logo
BRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion Cancers
December 4, 2017 / 11:50 AM / 14 days ago

BRIEF-Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability Of Response In TRK Fusion Cancers

Dec 4 (Reuters) - Loxo Oncology Inc:

* LOXO ONCOLOGY ANNOUNCES UPDATED LAROTRECTINIB PEDIATRIC CLINICAL TRIAL DATA DEMONSTRATING CONTINUED DURABILITY OF RESPONSE IN TRK FUSION CANCERS

* LOXO ONCOLOGY INC - LAROTRECTINIB DEMONSTRATES CENTRAL NERVOUS SYSTEM ACTIVITY WITH FIRST-EVER TRK FUSION GLIOBLASTOMA RESPONSE WITH A TRK INHIBITOR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below